IRLAB appoints Roy Jonebrant as interim CFO
Gothenburg, Sweden, August 21, 2025 — IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that Roy Jonebrant will take over as acting CFO on September 1, 2025.
Gothenburg, Sweden, August 21, 2025 — IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced that Roy Jonebrant will take over as acting CFO on September 1, 2025.
Roy Jonebrant replaces Viktor Siewertz, who is leaving IRLAB to take a senior position in another company, as previously announced.
"We are very pleased that Roy Jonebrant will take on the role of interim CFO during the recruitment process for a permanent successor to Viktor Siewertz. Roy's extensive experience from listed life science companies will be a great asset to IRLAB", says Kristina Torfgård, CEO.
Roy Jonebrant is senior CFO and finance executive with extensive experience in financial management, corporate affairs, and business development. He has held senior financial positions with IR responsibility at several life science companies and has worked closely with executive teams and boards, where he has driven acquisitions, divestments, and share issues. In recent years, he has taken on several assignments as interim CFO for listed MedTech and pharmaceutical development companies.